Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio
about
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myelomaAdditional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patientsAMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndromeTreating brain tumors with PDE4 inhibitorsTargeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidenceTowards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapyBiased and g protein-independent signaling of chemokine receptorsConcise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilizationTargeting bone physiology for the treatment of metastatic prostate cancerTargeting the molecular and cellular interactions of the bone marrow niche in immunologic diseaseTumor stroma as targets for cancer therapyCXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activityMLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonismPeripheral stem cell collection: from leukocyte growth factor to removal of catheter.G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinomaPlerixaforAn effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixaforThe CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patientsPredicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Haematopoietic stem cell transplantation for autoimmune diseases.Emerging therapeutic targets for synovial sarcoma.Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experienceSafety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonistEx vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.Significant mobilization of both conventional and regulatory T cells with AMD3100.
P2860
Q24186469-12D67584-A188-4F69-9047-77845A87D44DQ24202384-F6E2FCD8-020F-48BB-9FD2-E4FD23FDEF3CQ24623703-E76509BF-C7AD-4C0E-BF71-EEE205F2C2C0Q24628917-8CD8253F-D0E2-4A21-973E-286812635F13Q26770388-1AA29E3B-4A28-4C5C-9CDA-34299F3E24C6Q26771159-E619B4D5-CADE-4ECD-B644-16EEA85B9960Q26823970-9BFCD851-50E7-4524-998E-35C101B62FCFQ26825518-21BE3210-67C0-4D06-A9F7-D7BC16956F89Q26863249-CCD2E99D-9E2B-43CF-8B5F-57DF7E9E1461Q26865498-C6A4792E-BCAE-41D2-9975-093E221B40B2Q27015980-999C180D-A540-4D96-9DCE-272168531B26Q28587353-794C51F6-9D15-4594-A14B-FBEB6613E411Q28658170-7FCCD061-B124-4872-9741-1BD98F3E2ABEQ30458178-294C070D-9CB8-46A4-8C20-60846C9718ABQ30500067-62E9151E-59F5-4D1C-A407-68559F2C9343Q33411277-F62E479B-27B2-4296-90E3-47BB3492BC97Q33425816-5C79A0C7-8AE1-42F9-8550-A3C076A81DF5Q33543723-2D0D5609-C296-40BD-AA53-423966B7EA10Q33627439-AAE53940-B6F4-4076-AB93-30190FFB07DDQ33775283-E7151F3D-2EFC-4AD5-B029-BB01C430B985Q33885517-7F896852-DF48-495E-9117-2023B714A9C1Q34016950-01F4B631-3E03-47F0-BE5E-28399B129412Q34073741-635F0B56-5B05-443C-BC7A-F24E6ADC5521Q34114055-FE776FC0-DD3C-4249-873D-4D23C64B18BDQ34194325-F86374BD-171E-4889-B363-9D8C3111A81EQ34209313-3A1EC50F-E52C-4E70-9AC0-7D5BD3EA5A5FQ34213411-C2FD75F4-9EEC-42B8-9452-27F0620070CDQ34265754-DFA4671C-73A9-4B71-A15F-90FADED6C0CBQ34377450-BD92F547-B528-48AA-BD64-9EA9FD05BA84Q34403975-0103EB53-B0C4-4CCA-AE04-14018FADCBB3Q34432943-5912C3FE-5B5F-40AA-803B-8EBC7ED5CC15Q34454624-180BC376-0BAA-4C7A-BBF9-FE027BD323E8Q34490998-5629B4BB-0BB8-4163-BB60-D3EBAF56F1DEQ34551863-74331414-4BF4-48D3-BE3B-EBE4114F23C8Q34660607-81CEB63D-861B-4DB4-8B68-E8324FBC7903Q34762492-C6C8AFEA-9777-4B69-BA36-1E7F12D864FCQ34971081-0AACA227-78D5-4E93-BF1F-8B5604B464BEQ35230245-BA6EA68B-322B-4051-88E2-CD7438098794Q35563121-508CB8CA-8382-45E8-8A92-DF8E36EF4DB1Q35623657-2C81D8F4-3B7F-4415-A298-D510EE4053F0
P2860
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase III prospective randomiz ...... obilization and transplantatio
@en
Phase III prospective randomiz ...... obilization and transplantatio
@nl
type
label
Phase III prospective randomiz ...... obilization and transplantatio
@en
Phase III prospective randomiz ...... obilization and transplantatio
@nl
prefLabel
Phase III prospective randomiz ...... obilization and transplantatio
@en
Phase III prospective randomiz ...... obilization and transplantatio
@nl
P2093
P356
P1476
Phase III prospective randomiz ...... obilization and transplantatio
@en
P2093
3101 Investigators
Auayporn Nademanee
Brian J Bolwell
Eric Jacobsen
Gary Bridger
Gary Calandra
Ivana N Micallef
John F DiPersio
John McCarty
Patrick J Stiff
P304
P356
10.1200/JCO.2008.20.7209
P407
P577
2009-08-31T00:00:00Z